At a glance: 4 S&P 500 names report today — Lumentum and Bio-Techne, plus Supermicro, all after the close, and Cardinal Health before the open.

The tape ahead

Two AI-infrastructure names bookend a health-care distributor and a life-science tools name today — a split slate with very different setups.

Lumentum (after the close): consensus EPS of $2.97 versus $2.37 last quarter, up 25.3% vs.prev.Q, on revenue of $987.7M, up 22.2% vs.prev.Q — both well above the $0.88 EPS printed a year ago. The print sits squarely in the AI-optics supercycle: the 1.6T transceiver ramp, EML laser-chip demand and scale-across products (optical circuit switches, pump lasers) are the drivers, with supply constraints the main risk to further upside rather than demand. The sequential growth here isn't a clean read against history — the negative 3- and 5-year EPS CAGRs (-48%, -27%) reflect how deep the prior optical downturn cut before this rebound. At 11.1% the implied move is priced far above the 3.0% average realized move over the last eight prints, and against a perfect 8-for-8 beat streak that looks rich. Sentiment has been more mixed than the beat streak implies, though — price targets have kept climbing even as the stock has seen sharp pullbacks on valuation and insider-selling concerns.

Cardinal Health (before the open): consensus EPS of $2.42 versus $3.17 last quarter, down 23.6% vs.prev.Q, on revenue of $65.11B, up 6.8% vs.prev.Q. The sequential drop is seasonal rather than a warning sign — distribution volumes typically run hotter in the fiscal third quarter than the fourth — and against the $2.08 printed a year ago, consensus still implies solid double-digit YoY growth. The debate is whether specialty distribution (running above a $50B annual pace) and GLP-1 volume growth can keep offsetting IRA-driven pricing pressure and tariff cost absorption; guidance has already been raised more than once this year. At 6.9% the implied move sits just above the 6.4% historical realized average, a fair-to-modestly-rich setup backed by a perfect beat streak and a strong +13.7% surprise last quarter. The eye-catching +87% 1-year EPS CAGR is a low-base artifact from a depressed prior year rather than a clean growth signal; the steadier +5.9% 10-year figure is the better read on the underlying trend.

Supermicro (after the close): consensus EPS of $0.96 versus $0.84 last quarter, up 14.0% vs.prev.Q, on revenue of $11.56B, up 12.9% vs.prev.Q. Much of tonight's print is already known: Supermicro pre-announced preliminary results in July, guiding gross margins to 15–17% — roughly double its original 8.2–8.4% guide, on favorable customer and product mix — alongside a record order backlog above $60B, even as revenue landed near the low end of its $11.0–12.5B range. The stock already jumped sharply on that news, so tonight is mostly about the pieces the preliminary release didn't cover: opex, tax rate, and whether the margin beat holds through to the bottom line. The 13.8% implied move sits well above the 5.0% historical realized average, an unusually rich straddle for a name that has already told the market most of what it needs to know. History here is also the shakiest of today's four — just a 50% beat rate and the widest estimate range on the board ($0.57–$1.66 across 17 estimates), even after a +34.5% surprise last quarter.

Bio-Techne (after the close): consensus EPS of $0.52 versus $0.53 last quarter, down 2.0% vs.prev.Q, on revenue of $314.5M, up 1.0% vs.prev.Q — essentially flat against the $0.53 printed a year ago. That's by design: fiscal Q4 guidance has called for flat YoY growth, with roughly 150bp of drag from Fast Track-designated cell-therapy customers pulling GMP-protein orders forward into earlier periods, a headwind set to roll off entering fiscal 2027. The offset to watch is China, which has strung together several consecutive quarters of positive growth after a long stretch of weakness — a read-through worth flagging for other life-science tools names with China exposure. At 3.2% the implied move is priced below the 6.7% historical realized average, unusually cheap given a 62% beat rate and a narrow -0.8% miss last quarter that leave the outcome genuinely uncertain. Trailing EPS CAGRs are negative across every window (1Y -56%, 3Y -35%, 5Y -21%, 10Y -4%), a reminder of how prolonged the growth drought has been even as the sequential numbers and the China recovery point toward stabilization.

Scorecard — reported since we last wrote

Two names to score from Monday's slate. Simon Property Group's headline EPS beat is enormous — $3.29 actual against a $1.57 consensus, a 109.5% surprise — but the number is skewed by an unusually low prior-quarter base ($1.22); mall-REIT GAAP EPS swings hard on property-sale gains, impairments and depreciation timing rather than core operations, and the +169.7% sequential jump the table shows should be read the same way, not as a clean growth rate. Revenue beat by a smaller 11.0%. Despite the blowout EPS number, the stock actually dipped slightly after the close (-0.28%, AH) — a reaction that runs counter to the size of the surprise, consistent with the market discounting the distorted GAAP figure and keying off funds-from-operations and core operating metrics instead. Ferguson Enterprises's print was more straightforward: EPS beat by 2.8%, revenue by 1.8%, and the stock rose 2.76% in the regular session — a clean, proportionate reaction to a modest, in-line beat.

Rest of the week

Three sessions left. Wednesday is the busiest, headlined by Cisco — the week's largest name by market cap — alongside Coherent, Amcor and Trimble. Thursday closes out the week with Applied Materials and Tapestry.

Informational only — not investment advice. Figures are consensus/estimates and option-implied values from public sources and may be revised.